Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir plus nafamostat versus favipiravir alone for COVID-19 pneumonia
jRCTs031200026Completed
- Sponsor
- University of Tokyo
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing Favipiravir + nafamostat mesilate + standard treatment with Favipiravir + standard treatment (2 arms). Primary endpoint: Change in patient condition on a 10-point scale from baseline to day 7. Started Jun 2020; status: completed.
02
Drugs
favipiravirNafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs031200026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200026.